Clinical trials: System Sclerosis
Multiple Sclerosis, Diabetes
An Observational Post-Marketing Safety Registry of Sativex®
The purpose of this registry is to monitor safety outcomes of patients who are receiving Sativex® for Multiple Sclerosis (MS) spasticity and for off-label indications in the United Kingdom (UK), Germany and Sweden.
- Conditions
- Multiple Sclerosis, Diabetes, Cancer, Neuropathic Pain
- Trial name
- NCT02073474
- Testing
- Sativex®
- Volunteers
- 978 people
- Sponsor
- Jazz Pharmaceuticals
ALS (Amyotrophic Lateral Sclerosis), Postpoliomyelitis Syndrome
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
Motor neuron disease (MND) or ALS is a nervous system disease. ALS leads to a loss of movement ability that eventually leads to death. At the moment, there is no known treatment for ALS.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), Postpoliomyelitis Syndrome, Spinal Muscular Atrophy
- Trial name
- MotorMarker (NCT05663008)
- Testing
- 128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)
- Where
- Ireland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
Multiple Sclerosis, RRMS
Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?
The MYTH-MS study is a multicenter prospective study investigating the occurrence of clinical relapses in patients with relapsing-remitting multiple sclerosis (RRMS) in the absence of radiological activity on MRI.
- Conditions
- Multiple Sclerosis, RRMS, Multiple Sclerosis (MS) - Relapsing-remitting
- Trial name
- MYTH-MS (NCT07545889)
- Testing
- Early Cerebro-spinal MRI, Biomarker Assessment, Clinical and Neuropsychological Evaluations
- Where
- 8 sites in France
- Volunteers
- 136 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis
Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
The study is designed to determine the effect of weekly intramuscular (IM) administration of 30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and T2-weighted cranial magnetic resonance imaging…
- Trial name
- Avonex China (NCT01181115)
- Testing
- Avonex
- Where
- 10 sites in China
- Volunteers
- 60 people
- Sponsor
- Biogen
Multiple Sclerosis
Comparative Effectiveness Study Telerehab Versus Conventional
This study aims to compare the effectiveness of an exercise program delivered in a conventional facility-based format versus a telerehabilitation format, which takes place in the home.
- Trial name
- NCT03468868
- Testing
- Exercise program for people with MS
- Where
- 9 sites in United States
- Volunteers
- 379 people
- Sponsor
- Shepherd Center, Atlanta GA
Multiple Sclerosis
Impact of Adding Cognitive Behaviour Therapy to Supervised Pilates-based Core Stability Training in Patients With Multiple Sclerosis
To investigate the effect of adding cognitive behaviour therapy to supervised Pilates-based core stability training on balance, walking, fatigue and function in patients with multiple sclerosis
- Trial name
- MS (NCT05993819)
- Testing
- pilates based core stability training and congnitive therapy, Pilates based core stability training
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
Multiple Sclerosis
Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis
Dance Dance Revolution (DDR) may offer an innovative and highly effective format for delivering exercise programs to people with multiple sclerosis (MS).
- Trial name
- NCT01780792
- Testing
- Dance Dance Revolution video game play
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT06373081
- Testing
- Anti-CD19-CD3E-CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai Changzheng Hospital
Progressive Multiple Sclerosis
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS).
- Trial name
- NCT06675864
- Testing
- rapcabtagene autoleucel (YTB323)
- Where
- 18 sites in Australia, Canada and 5 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Developmental and Epileptic Encephalopathy, Dravet Syndrome
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
- Conditions
- Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox Gastaut Syndrome
- Trial name
- PACIFIC (NCT05364021)
- Testing
- LP352
- Where
- 34 sites in United States, Australia
- Volunteers
- 52 people
- Sponsor
- Longboard Pharmaceuticals
Multiple Sclerosis
Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients
This is a Phase 0/1 study of MS patients to determine the safety and potential efficacy of a novel, small human peptide designated as JM-4.
- Trial name
- NCT03887065
- Testing
- JM-4
- Volunteers
- 15 people
- Sponsor
- Cook, Stuart, MD
Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis)
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
- Conditions
- Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis), Motor Neuron Disease, ALS - Amyotrophic Lateral Sclerosis
- Trial name
- NCT07543367
- Testing
- Stentrode
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Synchron, Inc.
Multiple Sclerosis
Combating Age-related Failure of Myelination in Multiple Sclerosis: An Exploratory Study
This observational, longitudinal study will examine whether physical activity and other potentially modifiable lifestyle factors are associated with changes in myelin, the protective coating around nerve fibers, in older adults…
- Trial name
- MAPMyeMS (NCT07723599)
- Testing
- Observation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Washington
Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic Lateral Sclerosis
ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach
RNALS is a multicentre, transversal, diagnostic and non-interventional study carried out in ALS reference centers; in order to identify a diagnostic signature for Amyotrophic Lateral Sclerosis by analyzing of coding and…
- Trial name
- RNALS (NCT05928416)
- Testing
- Saliva sample
- Where
- 19 sites in France
- Volunteers
- 653 people, healthy volunteers welcome
- Sponsor
- ZIWIG
Relapsing Remitting Multiple Sclerosis
Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
The investigators hypothesize that Mycobacterium avium paratuberculosis positive Relapsing Remitting MS subjects will have a greater response to Interferon beta-1a therapy plus RHB-104 than from Interferon beta-1a alone.
- Trial name
- CEASE-MS (NCT01717664)
- Testing
- RHB-104
- Where
- 2 sites in Israel
- Volunteers
- 18 people
- Sponsor
- RedHill Biopharma Limited
Amyotrophic Lateral Sclerosis (ALS)
A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of VGN-R13 as a treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT06849609
- Testing
- VGN-R13
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Hong Chen
Multiple Sclerosis, Relapsing-Remitting
Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
This is a randomized, parallel group, placebo-controlled study designed to assess whether GSK239512 can enhance lesion remyelination in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01772199
- Testing
- GSK239512
- Where
- 43 sites in Bulgaria, Canada and 6 more
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes…
- Trial name
- NCT00649792
- Testing
- Fampridine-SR
- Where
- 42 sites in United States, Canada
- Volunteers
- 214 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis, Relapsing-Remitting
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.
- Trial name
- RIFUND-MS (NCT02746744)
- Testing
- Rituximab, Dimethyl fumarate, Sodium Chloride solution
- Where
- 17 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Anders Svenningsson
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Optic Neuritis, Eye Diseases
- Trial name
- RETIMUS (NCT04289909)
- Testing
- Adaptive Optics Ophthalmoscopy (AOO)
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.